Ask AI

Capsule Summaries

Share

Program Content

Activities

  • EMBRACE: N6LS Safety and Tolerability
    EMBRACE: Safety and Tolerability of VH3810109 (N6LS) in People With Virologically Suppressed HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 22, 2025

  • CLARITY
    CLARITY: Comparison of Long-Acting Injectable Antiretrovirals in Healthy Adults Without HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 22, 2025

  • PURPOSE 2 Subanalysis
    PURPOSE 2 Subanalysis: Annual Persistence on Twice-Yearly LEN vs Daily FTC/TDF for PrEP Among Cisgender Men and Gender-Diverse People
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 22, 2025

  • Weekly Oral ISL and LEN
    Once-Weekly Oral ISL + LEN in People Living With Virologically Suppressed HIV: Wk 96 Results
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 23, 2025

  • ACTG A5391 DO IT Metabolic Analysis
    ACTG A5391/DO-IT: Metabolic Parameters and Body Composition After Switch to DOR ± TDF vs Continuing INSTI + TAF/FTC 
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 23, 2025

  • Weight Gain in P052 Study
    P052 (MK-8591A-052) Phase III Trial of Switch From BIC/FTC/TAF to Doravirine/Islatravir: Impact on Weight and Body Composition at Wk 48
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 23, 2025

  • EMPOWER
    EMPOWER: Treatment Satisfaction of People Living With Virologically Suppressed HIV on LA ART Who Switched to Daily Oral BIC/FTC/TAF
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 23, 2025

  • Lenacapavir Teropavimab Zinlirvimab
    Phase II Study of Lenacapavir, Teropavimab, and Zinlirvimab in People Living With Virologically Suppressed HIV: Wk 52 Results
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 23, 2025

  • PREFER-LA
    PREFER-LA: Switch to LA CAB + RPV in People Living With HIV and Previous Adherence Challenges
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2025

  • LEN PrEP in Substance Use
    PURPOSE 2: Adherence to and Safety of Lenacapavir for PrEP Among People Who Use Substances
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare